Melanoma microenvironment-impact of modern therapies

被引：0

作者：

Sirokay, Judith ^{[1
]}

Mauch, Cornelia ^{[2
]}

机构：

[1] Univ Klinikum Bonn, Klin & Poliklin Dermatol & Allergol, Gebaude 11,Venusberg Campus 1, D-53127 Bonn, Germany

[2] Univ Klinikum Koln, Klin Dermatol & Venerol, Cologne, Germany

来源：

DERMATOLOGIE | 2022年 / 73卷 / 12期

关键词：

Immunotherapy; Targeted therapy; New therapeutic strategies; Therapeutic response; Systemic therapies; TUMOR-ASSOCIATED MACROPHAGES; PD-1; EXPRESSION; INFLAMMATION; NIVOLUMAB; CANCER; CELLS;

D O I：

10.1007/s00105-022-05078-2

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Background A considerable proportion of patients with advanced melanoma succumb to metastatic disease despite the initial success of modern therapies. Objectives An overview of the melanoma tumor microenvironment with special focus on approved therapies and new innovative strategies is given. Methods Current clinical trials and scientific insights concerning the impact of the tumor microenvironment on progression and therapy of advanced melanoma are reviewed and discussed. Results The tumor microenvironment with its manifold components and interactions plays a major role in the treatment of malignant melanoma. Conclusion Innovative new strategies that target an immunosuppressive microenvironment may improve the therapeutic efficacy of current treatment of advanced melanoma.

引用

页码：907 / 914

页数：8

共 29 条

[1] Ultraviolet-radiation-induced inflammation promotes angiotropism and metastasis in melanoma
Bald, Tobias
Quast, Thomas
Landsberg, Jennifer
Rogava, Meri
Glodde, Nicole
Lopez-Ramos, Dorys
Kohlmeyer, Judith
Riesenberg, Stefanie
van den Boorn-Konijnenberg, Debby
Hoemig-Hoelzel, Cornelia
Reuten, Raphael
Schadow, Benjamin
Weighardt, Heike
Wenzel, Daniela
Helfrich, Iris
Schadendorf, Dirk
Bloch, Wilhelm
Bianchi, Marco E.
Lugassy, Claire
Barnhill, Raymond L.
Koch, Manuel
Fleischmann, Bernd K.
Foerster, Irmgard
Kastenmueller, Wolfgang
Kolanus, Waldemar
Hoelzel, Michael
Gaffal, Evelyn
Tueting, Thomas
[J]. NATURE, 2014, 507 (7490) : 109 - +
[2] Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma
Chesney, Jason A.
Ribas, Antoni
Long, Georgina, V
Kirkwood, John M.
Dummer, Reinhard
Puzanov, Igor
Hoeller, Christoph
Gajewski, Thomas F.
Gutzmer, Ralf
Rutkowski, Piotr
Demidov, Lev
Arenberger, Petr
Shin, Sang Joon
Ferrucci, Pier Francesco
Haydon, Andrew
Hyngstrom, John
van Thienen, Johannes, V
Haferkamp, Sebastian
Guilera, Josep Malvehy
Rapoport, Bernardo Leon
VanderWalde, Ari
Diede, Scott J.
Anderson, James R.
Treichel, Sheryl
Chan, Edward L.
Bhatta, Sumita
Gansert, Jennifer
Hodi, Frank Stephen
Gogas, Helen
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (03) : 528 - +
[3] Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma
Diab, Adi
Tykodi, Scott S.
Daniels, Gregory A.
Maio, Michele
Curti, Brendan D.
Lewis, Karl D.
Jang, Sekwon
Kalinka, Ewa
Puzanov, Igor
Spira, Alexander, I
Cho, Daniel C.
Guan, Shanhong
Puente, Erika
Tuan Nguyen
Hoch, Ute
Currie, Sue L.
Lin, Wei
Tagliaferri, Mary A.
Zalevsky, Jonathan
Sznol, Mario
Hurwitz, Michael E.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (26) : 2914 - +
[4] Molecular, clinicopathological, and immune correlates of LAG3 promoter DNA methylation in melanoma
Froehlich, Anne
Sirokay, Judith
Fietz, Simon
Vogt, Timo J.
Dietrich, Joern
Zarbl, Romina
Florin, Mike
Kuster, Pia
Saavedra, Gonzalo
Valladolid, Susana Ramirez
Hoffmann, Friederike
Flatz, Lukas
Ring, Sandra S.
Golletz, Carsten
Pietsch, Torsten
Strieth, Sebastian
Brossart, Peter
Gielen, Gerrit H.
Kristiansen, Glen
Bootz, Friedrich
Landsberg, Jennifer
Dietrich, Dimo
[J]. EBIOMEDICINE, 2020, 59
[5] PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
Gordon, Sydney R.
Aute, Roy L. M.
Dulken, Ben W.
Hutter, Gregor
George, Benson M. .
Ccracken, Melissa N. M.
Gupta, Rohit
Tsai, Jonathan M. .
Sinha, Rahul
Corey, Daniel
Ring, Aaron M. .
Connolly, Andrew J.
Weissman, Irving L.
[J]. NATURE, 2017, 545 (7655) : 495 - +
[6] B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma
Griss, Johannes
Bauer, Wolfgang
Wagner, Christine
Simon, Martin
Chen, Minyi
Grabmeier-Pfistershammer, Katharina
Maurer-Granofszky, Margarita
Roka, Florian
Penz, Thomas
Bock, Christoph
Zhang, Gao
Herlyn, Meenhard
Glatz, Katharina
Laubli, Heinz
Mertz, Kirsten D.
Petzelbauer, Peter
Wiesner, Thomas
Hartl, Markus
Pickl, Winfried F.
Somasundaram, Rajasekharan
Steinberger, Peter
Wagner, Stephan N.
[J]. NATURE COMMUNICATIONS, 2019, 10 (1)
[7] In vivo switching of human melanoma cells between proliferative and invasive states
Hoek, Keith S.
Eichhoff, Ossia M.
Schlegel, Natalie C.
Doebbeling, Udo
Kobert, Nikita
Schaerer, Leo
Hemmi, Silvio
Dummer, Reinhard
[J]. CANCER RESEARCH, 2008, 68 (03) : 650 - 656
[8] Targeting inflamed and non-inflamed melanomas: biological background and clinical challenges
Indini, Alice
Massi, Daniela
Pirro, Matteo
Roila, Fausto
Grossi, Francesco
Sahebkar, Amirhossein
Glodde, Nicole
Bald, Tobias
Mandala, Mario
[J]. SEMINARS IN CANCER BIOLOGY, 2022, 86 : 477 - 490
[9] From inflammation to cancer
Korniluk, A.
Koper, O.
Kemona, H.
Dymicka-Piekarska, V.
[J]. IRISH JOURNAL OF MEDICAL SCIENCE, 2017, 186 (01) : 57 - 62
[10] Immunomodulatory Properties of Immune Checkpoint Inhibitors-More than Boosting T-Cell Responses?
Kuske, Michael
Haist, Maximilian
Jung, Thomas
Grabbe, Stephan
Bros, Matthias
[J]. CANCERS, 2022, 14 (07)

← 1 2 3 →